Stratification by MYC expression has prognostic impact in MYC translocated B‐cell lymphoma—Identifies a subgroup of patients with poor outcome

• Published in: European journal of haematology Vol. 102; no. 5; pp. 395 - 406
• Main Authors: Pedersen, Mette Ølgod, Gang, Anne Ortved, Clasen‐Linde, Erik, Breinholt, Marie Fredslund, Knudsen, Helle, Nielsen, Signe Ledou, Poulsen, Tim Svenstrup, Klausen, Tobias Wirenfeldt, Høgdall, Estrid, Nørgaard, Peter
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2019
• Subjects: B-cell lymphoma; Bcl-6 protein; BCL2; B‐cell; Cyclophosphamide; Doxorubicin; Etoposide; Fluorescence in situ hybridization; fluorescent in situ hybridization; Immunoglobulins; Immunohistochemistry; Lymphocytes B; Lymphoma; Monoclonal antibodies; MYC; Myc protein; Prednisone; prognostic; Protein expression; Protein transport; Proteins; Rituximab; Targeted cancer therapy; Vincristine; WHO; prognostic; fluorescent in situ hybridization; B-cell; MYC; lymphoma; BCL2; immunohistochemistry; WHO

Objective In patients with large B‐cell lymphoma (LBCL) according to WHO, the prognostic significance of MYC translocation is still not sufficiently clarified. We therefore aimed to investigate whether prognostication could be improved in patients with MYC translocation positive LBCL by additional s...